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Abstract: Albuminuria in individuals whose body mass index exceeds 40 kg/m2 is associated 
with the presence of large glomeruli, thickened basement membrane and epithelial cellular 
(podocyte) distortion. Obstructive sleep apnea magnifies glomerular injury as well, probably 
through a vasoconstrictive mechanism. Insulin resistance from excess fatty acids is exacerbated 
by decreased secretion of high molecular weight adiponectin from adipose cells in the obese 
state. Adiponectin potentiates insulin in its post-receptor signaling resulting in glucose oxida-
tion in mitochondria. Recent studies of podocyte physiology have concentrated on the structural 
and functional requirements that prevent glomerular albumin leakage. The architecture of the 
podocyte involves nephrin and podocin, proteins that cooperate to keep slit pores between foot 
processes competent to retain albumin. Insulin and adiponectin are necessary for high-energy 
phosphate generation. When fatty acids bind to albumin, the toxicity to proximal renal tubules 
is magnified. Albumin and fatty acids are elevated in urine of individuals with obesity related 
nephrotic syndrome. Fatty acid accumulation and resistin inhibit insulin and adiponectin. Study 
of cytokines produced by adipose tissue (adiponectin and leptin) and macrophages (resistin) 
has led to a better understanding of the relationship between weight and hypertension. Leptin, 
is presumably secreted after food intake to inhibit the midbrain/ hypothalamic appetite centers. 
Resistance to leptin results in excess signaling to hypothalamic sympathetics leading to hyper-
tension. Demonstration of the existence of a cerebral receptor mutation provide evidence for a 
role in hypertension of a central nervous reflex arc in humans. Further understanding of obesity-
related renal dysfunction has been accomplished recently using experimental models. Rapid 
weight loss following bariatric surgery may reverse renal pathology of obesity with restoration 
of normal blood pressure.
Keywords: glomerulomegaly, podocyte hypertrophy, obesity, albuminuria, adiponectin, 
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An association of body mass index (BMI) with risk of kidney disease was summarized 
from the Boston University Framingham study as a single unit increase of BMI 
accounting for a 20% increase of kidney disease over 20 years of follow up.1 A recent 
study from Copenhagen involving 20,000 women and 17,000 men aged 30–80 years 
found that for each 10% increase in BMI, the systolic blood pressure was 2.0–6.0 mm 
Hg higher along with an increase in diastolic pressure of 1–3 mm Hg.2 Visceral adipose 
was quantified by CT scan in a study from Laval University, Quebec.3 A significant 
correlation between mass of visceral adipose and level of blood pressure was noted. 
Kidney donors who were obese, or who became obese during an 11 year follow up International Journal of Nephrology and Renovascular Disease 2009:2 40
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at the University of California, San Francisco were found 
to have higher blood pressure than nonobese kidney donors 
even though proteinuria and nitrogen waste products in the 
plasma were not different4
When obesity is accompanied by persistent proteinuria of 
greater than 1 gm/day, findings at light microscopy include 
focal, segmental and global sclerosis. As lesions progress, 
individuals may become dependent upon renal replacement 
therapy. Since obese individuals do relatively well from 
earlier stages of chronic kidney disease through the stage 
of hemodialysis, this group is an important component of 
individuals awaiting kidney transplantation. Investigators 
from the Department of Nephrology, University of 
Vienna have concluded from a review of 50,000 patients 
in the Austrian Dialysis Transplantation Registry that 
cardiovascular mortality was significantly decreased for BMI 
30–35 kg/m2 compared to less than 30 kg/m2.5 Individuals 
with obesity-related renal failure that is not complicated by 
accelerated hypertension or profound insulin resistance do 
well on hemodialysis because of residual function in their 
large kidneys, in contrast to smaller people with diminutive 
kidneys. Many patients have been overweight since 
adolescence. Although elevations of blood glucose and blood 
pressure may not have occurred until many years later, official 
statistics may label the cause as hypertensive nephrosclerosis 
or diabetic nephropathy. It is reasonable to assume that if 
obesity promotes pathologic renal changes or accelerates 
damage from other entities that loss of excess body weight 
would ameliorate such changes, as well as having a beneficial 
effect on glucose metabolism and blood pressure.
Proteinuria in obesity is associated 
with changes in structure 
of the epithelial cell of the 
glomerulus (podocyte): changes in 
pathophysiology of the glomerulus 
are better understood than those  
of the proximal tubule
Anatomical studies of the renal glomerulus 
correlate with the physiology of obesity
Investigators from the Autonomous University of Barcelona 
described a distinct obesity-related change in the renal 
glomerulus.6 Extremely obese individuals (BMI  40 kg/m2) 
undergoing renal biopsy during bariatric surgery were 
compared with a group of age-matched patients studied at 
the time of elective nephrectomy. Twenty-four hour protein 
excretion was statistically different: 100–340 in the bariatric 
group vs 100–120 mg/day (p = 0.01) in the non-obese group. 
Fasting blood sugar levels also were different 88–117 vs 
85–99 mg/dl (p = 0.02), respectively.
Light microscopic changes noted in the bariatric group, 
but not the nephrectomy group, included large glomeruli 
(glomerulomegaly), podocyte hypertrophy along with 
increased mesangial cellularity and extracellular matrix. On 
electron microscopy, only in the bariatric group were fusion 
of adjacent podocytes containing lipids and cytoskeletal 
filaments aligned parallel to the basement membrane found. 
From the pathology and nephrology departments of Nagasaki 
and Hiroshima Universities, histologic findings in an 
overweight population included glomerular basement mem-
brane thickening when proteinuria was 100–2000 mg/day.7 
Earlier stage obese patients reported from University Hos-
pital, Patras, Greece with urine albumin below 30 mg/day 
were also found to have basement membrane thickening on 
renal biopsy.8
In the aforementioned study by the Barcelona group, 
the largest glomeruli were found in those extremely obese 
patients who also had clinically apparent sleep apnea.6 
The kidney dysfunction of obesity may in part be due to 
altered physiology accompanying sleep apnea, a frequent 
comorbidity in these patients. Obesity is actually the 
best-documented risk factor for obstructive sleep apnea 
(OSA)9 OSA is now a well-recognized cause of systemic 
hypertension in a portion of affected patients, and the severity 
of OSA appears to positively correlate with the degree of risk 
for hypertension.10
An increased prevalence of proteinuria in obese patients 
with OSA was initially recognized at the University of 
Wisconsin.11 This group of investigators studied 34 obese 
patients with OSA documented by formal sleep study and 
34 patients whose sleep studies were negative for the disorder. 
Patients who had diabetes mellitus, arterial hypertension, 
hematuria, bacteriuria/pyuria, or a serum creatinine greater 
than 1.2 were excluded from participation. Statistical analysis 
between the two groups revealed no difference in age, weight 
(mean 112.7 kg in patients with OSA versus 109.2 kg in 
controls), height, or percentage above ideal body weight. 
Proteinuria (defined as 1+ or more on urinary dipstick) 
occurred in 47% of the patients with OSA versus 29% of the 
control group, and high-grade proteinuria (3 to 4+ on dipstick; 
3+ equating to 300 mg/dl and 4+ equating to 2000 mg/dl) 
was found in six patients with OSA but in none of the 
controls. Four patients able to be followed for 3 years, had 
improvement in proteinuria after therapy for OSA.International Journal of Nephrology and Renovascular Disease 2009:2 41
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Investigators from the Medical College of Georgia, 
Augusta12,13 observed nocturnal urinary protein excretion to 
be 16.2 ± 5.5 microgram/min in 9 healthy control subjects, 
29.3 ± 9.5 microgram/min in 12 obese subjects without OSA 
on sleep study, and 94.0 ± 13.8 microgram/min in 14 obese 
patients with documented OSA. Patients with known renal 
disease, diabetes mellitus, elevated serum creatinine, 
abnormal urine sediment, or uncontrolled hypertension 
were excluded in this study. More recently, a group at the 
University of Athens,14 studied microalbuminuria in hyper-
tensive patients with OSA versus hypertensive patients 
without OSA by formal polysomnography. Participants 
were matched for age, sex, smoking status, BMI, 24-hour 
pulse pressure, with exclusion if impaired glucose metabo-
lism and chronic kidney disease were detected. This group 
demonstrated that albuminuria was greater by 57% in 
hypertensive patients with OSA as compared with those 
without OSA. This group demonstrated that the number 
of apneas plus hypopneas per hour of sleep (AHI) as well 
as 24-hour pulse pressure were independent predictors 
of albuminuria in their multivariable linear regression 
model. Since albuminuria is a well-validated sign of diffuse 
endothelial dysfunction, these investigators hypothesized 
that such vascular dysfunction observed in OSA may 
engender the increased rate of cardiovascular morbidity 
and mortality seen in the disease. The pathophysiologic 
mechanism underlying the increased rate of proteinuria in 
OSA is incompletely understood.
Prospective studies of biopsy-proven focal glomerulo-
sclerosis demonstrate higher levels of proteinuria and more 
rapid progression of renal dysfunction when compared to 
the findings of the Barcelona investigators. The study group 
from Columbia University, in New York15 followed 71 patients 
whose renal biopsies were denoted “obesity- related 
glomerulopathy”, 50 with “pure” focal sclerosis, and 50 with 
“mixed” findings. Chronic renal dysfunction occurred in 
3.6% of the glomerulopathy group, 42% of the “pure” focal 
sclerosis group, and 4.0 % in the “mixed” group suggesting 
the mixed findings group was similar to the obesity-related 
glomerulopathy patients. As oxygen requirements of the 
medulla are higher than that of the cortex, it has been 
suggested that juxtamedullary nephrons would be more 
susceptible to hypoxemia and more likely to benefit from loss 
of weight.12 The most striking degree of glomerulomegaly 
observed in obese patients biopsied at the University of 
Texas, Houston was more evident in the cortex.16 Thus, 
while hypoxemia may be important in “pure” focal sclerosis 
of juxtamedullary nephrons, the role of hypoxemia in the 
increased glomerular size of obesity may be limited to 
individuals with superimposed sleep apnea.6
The presence of an inflammatory cascade contributing 
to mesangial expansion would be expected to accelerate 
sclerosis in obesity. Investigators at the Hospital of 
St. Etienne, University of Lyon studied the effect of 
obesity on 162 patients with IgA nephropathy (95 patients 
were lean, 67 were obese).17 Baseline renal biopsy in the 
67 obese patients showed higher grades of glomerular, 
tubulointerstitial, and vascular pathology in association with 
higher levels of proteinuria compared to controls. At the 
20-year follow up, 60 % of the obese group had become 
dialysis dependent as opposed to 10 % of the non-obese 
patients. A major mechanism in obesity-related inflammation 
is a deficiency in adiponectin, a protein secreted by adipose 
tissue. Adiponectin inhibits Tumor Necrosis Factor alpha, 
which activates Nuclear Factor kappa B (NFkB). Since 
NFkB initiates gene sequences for inflammation cascades, a 
deficiency of adiponectin has profound consequences for the 
pathophysiology of obesity-related inflammation.18
Table 1 compares the glomerulopathies of obesity, 
diabetes, and focal sclerosis. Loss of creatinine clearance 
is associated with mesangial cell proliferation, matrix 
expansion and progressive scarring to different degrees in 
these three causes of proteinuria.
Mechanisms of proteinuria  
in obesity-related glomerulopathy
Studies from Indiana University have focused on renal tubular 
handling of sodium in obesity and insulin resistance. Increased 
insulin levels promote proximal tubular absorption of sodium 
with decreased delivery to the distal tubule (macula densa), 
causing a feedback reflex that results in greater perfusion of 
the glomerulus.20 Increased proximal tubular resorption of 
Table 1 Pathology in proteinuria of obesity, type 2 diabetes, focal sclerosis
Glomerulus Podocyte Basement membrane Mesangium
Obesity Glomerulomegaly Fusion, linear deposits Thickened 2+ Increased 2+
Type 2 diabetes No Change Fusion Thickened 3+ Increased 4+
Focal sclerosis Epithelial Hyperplasia19 Fusion Thickened 4+ Increased 3+International Journal of Nephrology and Renovascular Disease 2009:2 42
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sodium is enhanced by hyperinsulinemia but countered by 
proximal tubular sodium wasting due to elevated levels of 
leptin seen in obesity.21 Higher aldosterone levels of obese 
compared with non-obese individuals also enhance tubular 
sodium resorption at a distal site in the collecting duct.22 On 
balance renal tubular resorption response to insulin appears 
more potent than the mixed response to leptin/aldosterone 
in obesity. The same relationship between BMI, aldosterone 
and sodium balance has also been demonstrated in normo-
tensive subjects.23
Increased filtered solute load due to turnover of the 
increased fat plus muscle content of extreme obesity along 
with increased plasma volume can be expected to enlarge 
glomerular capacity.24 Studies from Hopital Lapeyronie, 
Montpellier found glomerular filtration rate (GFR) increased 
in obese patients. Increased GFR associated with obesity 
and glomerulomegaly correlated with urinary excretion of 
urea and protein. This was supported by use of BUN as a 
marker for protein intake.25 Hyperinsulinemia of obesity was 
related to increased perfusion of muscle26 consistent with 
observations of increased perfusion of the nephron.20 Animal 
studies have demonstrated glomerulomegaly with high fat 
diet. When the obese Zucker rat lost weight as a result of a 
low calorie diet, there was a decrease in proteinuria associated 
with improvement in glomerulopathy.27
A human study from Hospital Universitario 12 de Octobre, 
Madrid found that a decrease in BMI from 33 to 31.6 kg/m2 
was associated with a fall in 24-hour urine protein from 2.8 
to 1.9 grams/day. The investigators studied patients with Type 
2 diabetes, hypertensive nephrosclerosis, focal sclerosis, 
mesangial glomerulonephritis, and reflux nephropathy. 
The control group consisted of ten obese patients on their 
usual diet, who gained 2 kg in 5 months. The diet group 
was allowed 500 kilocalories less than their usual daily 
intake, resulting in a loss of 3.6 kg in 5 months. These 
combined data generated a positive correlation between 
weight loss or gain and urine protein decrease or increase 
(p  0.01, r = 0.62) for the 30 study patients.28 Mechanisms 
described from Rabin Medical Center, Tel Aviv University 
have included hemodynamic alterations involving expanded 
plasma volume, increased renal plasma flow (RPF), increased 
GFR, and increased filtration fraction (GFR/RPF). Another 
mechanism is increased capillary filtration pressure.29 When 
gastric reduction surgery was used to cause loss of fat but not 
muscle in 8 obese individuals (BMI = 48.0 kg/m2) compared 
with 9 controls of normal body mass index (22.1 kg/m2), 
there was a weight loss of 48 kg over 12–17 months for a 
change in BMI of 15.9 kg/m2 as opposed to no change. GFR 
fell significantly from 144 to 110 ml/min in the obese group 
versus a value of 90 ml/min in the control group, which did 
not change. Renal plasma flow fell significantly from 803 to 
698 ml/min versus a control of 610 ml/min. Filtration fraction 
fell significantly from 0.178 to 0.158, versus control of 0.149. 
Systolic pressure fell from 143 to 133 mm Hg versus control 
of 120 mm Hg.29
The cellular physiology of the podocyte has become 
the focus of much new research. These epithelial cells have 
interconnected architectures with close-fitting foot processes 
that require a large amount of energy to function as a filtration 
barrier for albumin and fats, not only to preserve resources, 
but also to protect the proximal tubule from injury. This energy 
comes from oxidation of glucose and fatty acids. A key step is 
phosphorylation of the kinase of adenosine monophosphate 
whose activation is promoted by metformin.30 Glucose enters 
the podocyte through the glucose transporter protein complex 
(GLUT). Pioneering studies have identified cooperation of 
insulin and adiponectin in glucose transport across the podo-
cyte cell membrane. From the University of Bristol and from 
University College, London, the filtration barrier protein, 
nephrin, was found to be critical for movement of GLUT 
proteins across the cytosol for attachment to the cell surface 
membrane.31 Without nephrin, there is no quick energy for 
maintaining a barrier to loss of nutrients as a meal is being 
digested. Studies from the University of California at San 
Diego, Thomas Jefferson University, Philadelphia, and Baylor 
University, Houston have produced convincing evidence that 
adiponectin cooperates with insulin in the work of nephrin 
by co-activating adenosine monophosphate kinase (AMPK), 
a step just before oxidation of long-chain fatty acids is begun 
in mitochondria,32 Table 2.
Insulin resistance occurs in obesity due to a deficiency 
of active insulin receptors, an inhibition of oxidation of fatty 
acids related to a deficiency of adiponectin and inefficient 
secretion of insulin by beta cells associated with higher 
levels of leptin (Table 3). Normal feedback inhibition of 
insulin secretion by insulin itself retains intermittent or 
Table 2 Glomerular filtration barrier: Nephrin is assisted by 
oxidation of glucose fatty acid
Glucose transport Fatty acid disposal
Insulin + +*
Adiponectin + +*
Leptin ? ?
Resistin ? -
Note: *Promoted by metformin/acetyl l-carnitine.International Journal of Nephrology and Renovascular Disease 2009:2 43
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pulsatile secretion in contrast with inhibition of beta cell 
function by leptin. In combination with excess glucose the 
oscillation of calcium in the cytosol is inhibited, resulting 
in loss of pulsatile secretion, followed eventually by loss 
of adequate insulin non-pulsatile secretion.33 Adiponectin 
assists insulin in the liver by decreasing gluconeogenesis 
and glycogenolysis. Failure to process fatty acids due to 
a deficiency of adiponectin leads to their accumulation, 
which is in itself another cause of insulin resistance at the 
level of phosphfructokinase in the glycolytic cycle.34 The 
apparatus for post-receptor propagation of the insulin signal 
after binding to its receptor exists within muscle, adipose, 
and glomerular epithelial cells (podocytes) and can be 
inhibited by elevated levels of aldosterone.35 Aldosterone also 
promotes the generation of NADPH oxidase which inhibits 
the phosphorylation of AMPK at the last step before mito-
chondrial generation of high energy phosphate.36 Without 
a fundamental collaboration of nephrin, adiponectin and 
insulin, there would be insufficient energy to maintain the 
foot processes in correct position to occlude the slit pore. 
If protein and lipids were to appear in the glomerular filtrate, 
they would quickly damage the proximal tubule, particularly 
with the elevated concentrations seen in the nephrotic 
syndrome.
The cytocellular components actin and podocin utilize 
energy to position the community of foot processes. 
Occupation of the receptor for advanced glycated end 
products inhibits confluence of foot processes by inhibiting 
mitochondrial energy production.37 Since the unoccupied 
receptor is found precisely at the places where the foot 
processes must come together, inhibition of free movement 
with glycated end-products would have pathological 
consequences. Studies of the receptor for advanced glycated 
end products at Albert Einstein School of Medicine37 and 
Columbia University both in New York have brought the 
greatest clarity to mechanisms.38 It is now appreciated that 
the AGE carboxymethyl lysine has a higher potential for car-
diovascular cytotoxicity than carboxyethyl lysine39 or methyl 
glyoxal40 but there is no study as yet available pinpointing 
a pathological AGE for the podocyte. The receptor for 
advanced glycated end products is found precisely where 
endothelial injury and inflammation combine to initiate 
atherosclerosis and diabetic vascular pathology.41 The 
diabetes complications observed in survivors of insulin 
deficiency for greater than 50 years were limited to 
large vessel rather than microvascular disease.39 Diabetic 
congenital complications are related to a malformation of 
the aortopulmonary outflow tract.40 The current hypothesis 
is that carboxymethyl lysine has a major impact on the 
inflammatory cascade due to its generation in the setting 
of oxidative stress.
Studies of the renal proximal tubule 
are not yet specific to obesity-related 
glomerulopathy
Investigators from Shinshu University and the National 
Cancer Institute, Bethesda have focused on proximal tubular 
toxicity of fatty acids present in a model of nephrotic 
syndrome with hyperlipidemia.42 In their mouse model, 
although high concentrations of albumin were not toxic, 
16-carbon fatty acid (palmitic) bound to albumin caused 
severe injury to proximal tubular cells. In this model, the 
peroxisome proliferator activated receptor alpha (PPAR alpha) 
was found to be highly protective. In view of this finding, 
studies of pharmaceutical agents that activate renal PPAR 
alpha such as clofibrate are warranted. Using clofibrate these 
investigators found that in the nephrotic mouse successful 
elimination of excess fatty acid by increased beta-oxidation in 
mitochondria was associated with protection of the proximal 
tubule. However, the investigators warned that an increased 
generation of reactive oxygen species by mitochondria was 
detected. This would be of concern in the insulin resistant 
obese patient due to formation of advanced glycated end 
products. No proximal tubular site has yet been identified 
for injury related deposition of AGE at its receptor.
Table 3 Adiponectin, leptin and resistin interact with insulin in liver, pancreas, and kidney
Hepatic  
gluconeogenesis
Hepatic  
glycogenolysis
Glucose/ 
fatty acid 
disposal
Pancreatic beta 
cell function
Renal tubular Na 
resorption/wasting
Insulin Inhibits*** Inhibits Activates* Inhibits +/-
Adiponectin Inhibits*** Inhibits Activates* ? ?/?
Leptin ? ? ? Inhibits** + indirect/+ direct
Resistin Activates ? Inhibits** Inhibits ?
Notes: *Promoted by metformin/acetyl l-carnitine. **Promoted by aldosterone. ***Promoted by acetyl l-carnitine.International Journal of Nephrology and Renovascular Disease 2009:2 44
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Accumulation of fatty acids in muscle and liver has its 
own toxicity. Carnitine is essential for transportation of long-
chain fatty acids from cytoplasm to mitochondria. Deficiency 
of carnitine is associated with insulin resistance, hypertension 
and loss of the beneficial effects of adiponectin. Replacement 
of acetyl carnitine among type 2 diabetic patients studied 
at the Mario Negri Institute for Pharmacological Research 
in Bergamo43 restored insulin sensitivity and normal blood 
pressure as well as both total and high molecular weight 
adiponectin. Removal of excess fatty acids permits enzymes 
of glycolysis44 and gluconeogensis45 to return to normal 
function.
Experiments from Massachusetts General Hospital, 
Indiana University Medical Center and Victoria, Australia 
demonstrate that impaired uptake of albumin by the 
proximal tubule in streptozotocin-treated (ie, insulinopenic) 
diabetic rats is reversible with insulin.46 This malfunction 
was identified earlier in the course of diabetes than 
glomerular albumin leakage. There is no similar report as 
yet in the insulin resistant animal with diabetes-induced 
albuminuria.
Obesity carries with it a glomerular leak, relative 
insulin resistance, and increased fatty acids (reflected in 
the circulating triglycerides). If the obese insulin resistant 
animal model or patient were to respond entirely to insulin, 
there would be no proximal tubular toxicity. If however, 
the insulin resistant animal or patient were to respond in a 
similar manner to the insulinopenic STZ rat, then failure 
to correct the glomerular lesion entirely, while reversing 
tubular leakage, might result in greater toxicity to the 
proximal tubule. In many glomerular diseases duration 
of renal function is predicted by tubulointerstitial rather 
than glomerular pathology. We can conclude based upon 
current knowledge that insulin resistance has toxic potential 
on the podocyte through advanced glycated end-products 
and impaired metabolism of fatty acids. An increased 
concentration of fatty acids in the plasma and glomerular 
filtrate is toxic to proximal tubules when absorbed across 
the cell membrane in the presence of insulin, particularly 
when bound to albumin. In cultured human renal proximal 
tubular epithelial cells, aldosterone can increase expression 
of collagen III and IV that gives it a potential role in 
tubulointerstitial fibrosis by promoting tubular epithelial-
mesenchymal transition and collagen synthesis.47 This 
combination of profibrotic effects in tubular as well as 
mesangial cells can contribute to tubulointerstitial fibrosis 
with glomerular scarring. Type 2 diabetic kidney disease 
may well be another example of glomerular disease in 
which outcome is predicted by degree of tubulointerstitial 
inflammation/scarring
Hypertension of obesity may  
be exacerbated by altered levels 
of adipokines secreted by white 
adipose tissue
Adiponectin is the adipokine with highest 
concentration in the circulation
Adiponectin is secreted by white adipose tissue. Levels are 
higher in lean individuals who benefit from the effects of 
adiponectin in assisting insulin, which decreases gluco-
neogenesis. Low, intermediate and high molecular weight 
(HMW) forms of adiponectin are found in the circulation. 
Levels of HMW adiponectin fall with obesity. Studies from 
Munich, Maastricht and Leuven have further concluded that 
there is a decrease in concentration of HMW adiponectin 
in hypertensives with normal BMI.48 In Osaka decreased 
levels of HMW adiponectin were noted to be associated with 
ischemic heart disease49 in lean individuals. In Denver the 
only factor found to increase adiponectin in the lean children 
with chronic renal insufficiency was a decreased creatinine 
clearance.50 The other adipokines that are cleared by the 
kidney are leptin and resistin,51 factors that do not promote 
the function of insulin as adiponectin does (Table 4).
An important intracellular form of insulin resistance is 
inhibition of mitochondrial fatty acid oxidation associated 
with adiponectin deficiency and/or increased levels of resistin. 
As fatty acids accumulate, insulin resistance is magnified. 
The energy generated by fatty acid oxidation at the slit pore 
membrane maintains a filtration barrier for albumin and 
lipids. The point in the renal glomerulus where this activity 
occurs is referred to as the slit-pore or zona occludens of the 
community of podocytes. This is the very same anatomic 
point at which advanced glycated end products bind to 
their specific receptors. Adiponectin and leptin also both 
affect endothelial surfaces of vessels. HMW adiponectin is 
considered protective. Since leptin has both a sympathetic 
effect to constrict vessels without going through endothelium 
Table 4 Factors in blood levels of insulin and adipokines
Obese Lean Renal dysfunction
Insulin Increased Decreased Increased
Adiponectin Decreased Increased Increased
Leptin Increased Decreased Increased
Resistin Increased Decreased IncreasedInternational Journal of Nephrology and Renovascular Disease 2009:2 45
Manifestation of renal disease in obesity Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
and an indirect endothelial effect on nitric oxide release52 that 
dilates vessels with the potential for increased fluid leakage, 
it is not considered renoprotective.
Investigators from Melbourne divided 34 obese hypertensive 
patients into an insulin resistant (n = 19) and an insulin sensitive 
(n = 15) group by measuring multiple insulin and norepinephrine 
levels during an oral glucose tolerance test and evaluating the 
area under the curve.53 At baseline norepinephrine levels were 
higher and clearance of norepinephrine was lower in the insu-
lin-resistant group. With 12 weeks of life style modification, 
body weight fell by 8 kg in both study groups. Leptin levels 
fell significantly more in the insulin-resistant group. With 
weight loss and fall in leptin, a significant fall in level of 
norepinephrine was seen only in the insulin-resistant group. 
Thus, from this study we can conclude that in the absence of 
weight loss, treatment of blood pressure can be expected to be 
more difficult in the insulin resistant group.
Leptin levels are higher when there  
is an excess of white adipose
Leptin may also be secreted by muscle and placenta, leading 
to obstetrical difficulties such as pregnancy-induced hyper-
tension, intrauterine growth retardation, and pre-eclampsia 
according to studies from Portland, Oregon.33 To gain further 
insight into the relationship between leptin levels and blood 
pressure control, investigators from the Athens School of 
Medicine worked with non obese study subjects.54 They 
measured circulating levels of leptin and soluble leptin 
receptor of 494 (272 males, 222 females) individuals 
(BMI  30 kg/m2). 180 subjects were normotensive and 
314 had high blood pressure. Of the 314 hypertensive 
patients, 166 had fixed, 82 had white coat (abnormal in clinic, 
normal on ambulatory monitoring), and 66 had masked 
(normal in clinic, abnormal on ambulatory monitoring) 
blood pressure elevations. Leptin levels were significantly 
higher and soluble leptin receptor levels were significantly 
lower in individuals with fixed or masked hypertension 
when compared with subjects with normal blood pressure 
or white coat hypertension.
It has been hypothesized that increased concentrations 
of insulin and leptin may activate obesity related high blood 
pressure by stimulation (Table 5) of the central sympathetic 
nervous system (hypothalamus or nucleus tractus solitarius 
in midbrain).
The intermediate step between leptin and the midbrain 
sympathetic centers involves two transmitters known as 
neuropeptide Y and melanocortin. A mutation of the receptor 
for melanocortin is being studied in families with early-onset 
obesity followed at Addenbrooke’s Hospital, Cambridge.55 
There were two groups of study patients with obesity. The first 
group had a greater than 50% incidence of hypertension due to a 
functioning melanocortin signal through an intact receptor. The 
second had a less than 25% incidence of high blood pressure 
despite extreme obesity. In addition to lower blood pressure 
while awake there were slower heart rates with lower outputs of 
norepinephrine along with evidence for intact parasympathetic 
heart rate variation. Blood pressure and heart rate increased 
and heart rate variation decreased with an experimental agonist 
of the dysfunctional receptor. Raising leptin concentrations 
to achieve satiety does not result in weight loss and could 
conceivably exacerbate hypertension in obese patients.
The locus of the leptin post-receptor signal in mid brain, 
the melanocortin site, has been studied by investigators from 
the University of Mississippi56 Medical Center. The Sprague-
Dawley rat treated with STZ develops insulin deficiency hyper-
glycemia, hyperphagia and a slow heart rate. Intracerebral 
ventricular infusion of leptin reverses this clinical problem. 
An antagonist to the melanocortin receptor blocks leptin’s 
reversal of these acute insulin deficiency findings. An agonist 
to the melanocortin receptor eliminated the need for leptin 
but could only sustain the effect for several days unlike leptin, 
which appeared to permanently replace insulin. Thus, the 
Table 5 Mechanisms of hypertension in obesity
CNS sympathetic 
stimulation
Vasodilates Vasoconstricts
Insulin + +* + CNS
Adiponectin - + ?
Leptin + + +
  Endothelial dependant + -
  Nonendothial dependant - + CNS
  Resistin ? ? ?
Note: *Promoted by metformin.
Abbreviations: CNS, central nervous system.International Journal of Nephrology and Renovascular Disease 2009:2 46
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receptors for leptin and melanocortin represent an area of 
active investigation for both satiety and elimination of excess 
fuel via heat dissipation by brown adipose tissue.57
Another hypothesis suggests direct stimulation of the renin/
angiotenin/aldosterone system by a combination of excessive 
leptin and deficient adiponectin58 from white adipose tissue 
in the obese patient33,59 (Table 6). Other possible mechanisms 
include the release by white adipose tissue of the oxidative 
derivative form of linoleic acid60 and a releasing factor stimulat-
ing the secretion of mineralocorticoids by the adrenal cortex.61 
Small studies have shown that addition of spironolactone to 
renin angiotensin system blockade may reduce proteinuria and 
retard renal progression in chronic kidney disease patients.62 
Eplerenone, another aldosterone antagonist, has been shown to 
reduce albuminuria in patients with type 2 diabetes.63 It is not 
known whether aldosterone receptor blockade will be effective 
or of reasonable price for future clinical studies.
Resistin inhibits insulin in liver  
and possibly muscle and podocyte
Rodents secrete resistin from white adipose tissue (adipokine), 
however, humans secrete resistin from macrophages. Resistin 
increases with obesity and diminished renal function. 
Insulin resistance results from elevated levels of gluconeogenic 
enzymes and inhibition of mitochondrial generation of energy 
(inhibition of AMP kinase). Circulating resistin exists in 
several oligomeric forms. The roles of the different oligomers 
are not yet known. The endoplasmic reticulum is the locus 
for removal of some forms of resistin.64
Experimental animal models 
may clarify obesity-related kidney 
pathology
Mouse model
The obesity gene (ob) codes for leptin and is absent in 
the ob/ob mouse resulting in a phenotype of hyperphagia 
and physical inactivity. This obese animal model does not 
exhibit the renal pathology of obesity seen in other animal 
models theoretically due to an absence of leptin. The db 
gene controls the central nervous system receptor for leptin 
binding. Absence of this db gene encodes the CNS leptin 
receptor and renders the db/db mouse susceptible to high 
leptin obesity. This animal model exhibits glomerular 
pathology similar to that seen in obesity and type 2 diabetes. 
Investigators from the University of Pennsylvania Renal 
Electrolyte-Hypertension Division65 used an antibody to 
Transforming Growth Factor beta (TGF beta) to protect 
the kidney of the db/db mouse from its expected pathology. 
Because leptin has homology with Interleukin 6, it was 
hypothesized that leptin might stimulate an inflammatory 
cascade, involving TGF beta. Thus blockade at this level 
might be protective.
Use of mouse models for type 1 (Akita) and type 2 diabetes 
mellitus (db/db) have demonstrated that hyperglycemia66 
and advanced glycation end-products67 promote detachment, 
necrosis, and apoptosis of podocytes via enhanced 
expression of NADPH oxidase resulting in generation of 
reactive oxygen species. Studies of type 2 diabetic patients 
from the Pima nation in Arizona have demonstrated that 
a decreased number of podocytes can be detected prior to 
other changes in the glomerulus.68 It is possible that loss of 
podocyte nephrin will be understood as the transition step 
from an obesity-related to a diabetes-induced pathogenesis 
of proteinuria.69
Mouse angiogenesis model
Investigators from Denver, Ashikawa, and London have 
reviewed prior studies that employed the STZ diabetic rat 
(model of Type 1 Diabetes) and the db/db mouse (model 
of Type 2 Diabetes).70 In both models, hyperglycemia was 
associated with an increased capacity of the podocyte and 
proximal tubular cell to synthesize vascular endothelial 
growth factor (VEGF) A, which activates receptors on the 
capillaries of both glomerulus and proximal tubule lead-
ing to neovascularization similar to that observed in the 
retina.
Current epidemiological studies indicate a rapid increase 
in the prevalence of obesity in pre-adolescence71 and in 
adolescence.72 Even Type I diabetic patients may develop 
obesity. Obesity can begin so early in childhood that Type 2 
diabetes is possible before the age of 21 years. Information 
acquired from the study of obesity with or without insulin 
resistance will be useful in the study of the risk for blindness 
and kidney failure.
Table 6 Obesity-related hypertension: Role of central nervous 
and adrenal mechanisms
A.  Central nervous system: sympathetic stimulation
  1. Increased insulin via renin-angiotensin-aldosterone system
  2. Increased leptin via renin-angiotensin-aldosterone system
B.    White adipose
  1. Local renin-angiotensin-aldosterone system
  2. Mineralocorticoid releasing factors stimulating adrenal secretion
  3. Oxygenated fatty acid (linoleic) stimulating adrenal secretion
  4.   Absence of vasodilatory effect of adiponectinInternational Journal of Nephrology and Renovascular Disease 2009:2 47
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Vitamin D receptor deficient mouse: 
model for hyperreninemia
An experimental mouse model lacking the vitamin D receptor 
has been used to demonstrate an inhibition of renin secretion 
by juxtaglomerular cells following exposure to 1,25 dihydroxy 
vitamin D.73 Research from the University of Chicago and 
Northwestern has demonstrated that the interaction between 
vitamin D and renin is independent of the concentration of 
serum calcium or parathyroid hormone. Current appreciation 
of a high incidence of vitamin D deficiency in obesity has 
been supported by a demonstration of diminished capacity to 
respond to ultraviolet light or to oral supplementation in obese 
compared with lean subjects studied at Boston University 
School of Medicine.74 However, universal supplementation 
of Vitamin D without appropriate monitoring could be 
injurious by calcium phosphate deposition and has not been 
demonstrated to be renoprotective at present.
Active mineralocorticoid receptor  
mouse model
The Dahl salt-sensitive rat expresses elevated levels 
of blood pressure and aldosterone with salt in the diet. 
The mineralocorticoid receptor is activated under these 
conditions, but can be inhibited with eplerenone. In studies 
from the University of Tokyo Graduate School of Medicine, 
a mouse model has been developed that has spontaneous 
activation of the mineralocorticoid receptor even with low 
levels of aldosterone. Renal pathology includes podocyte 
injury with increased mesangial matrix.75 There is ongoing 
research in blocking activation of the mineralocorticoid 
receptor for preservation of renal function.
Integrin/kinase deficient mouse model
Integrin has been identified at the unique location on the 
foot process cytoskeleton that is central to orientation of 
the slit pore. Integrin linked kinase appears to be responsible 
for changes in slit pore conformation. A mouse model lacking 
a functional integrin linked kinase exhibits proteinuria before 
any anatomical abnormalities are discernable. This critical 
link between structure and function has been hypothesized 
to contribute to nephrosis.76 Transforming Nuclear Factor 
alpha promotes adhesion and expression of endothelial 
adhesion molecules. Deficiency of adiponectin is a stimulus 
to adhesion. When human aortic endothelial cells were used, 
vascular adhesion molecule (VCAM-1), endothelial leukocyte 
adhesion molecule (E-selectin), and intracellular adhesion 
molecule (ICAM-1) even in the presence of Transforming 
Nuclear Factor alpha were inhibited by adiponectin in a 
concentration-dependent proportion.77
Mouse model for obesity  
and diabetes (KKA/T)
Polyunsaturated fatty acids have been demonstrated to 
diminish urine albumin excretion, inhibiting expression of 
the inflammatory marker monocyte chemoattractant protein 
without an effect on GFR or blood pressure.78 In a meta 
analysis of 17 trials evaluating urinary protein excretion 
changes with administration of omega 3 fatty acids, it was 
concluded that urine protein excretion was diminished 
significantly (19%) over a median of 9 (range 1.5–48) 
months. Results in the diabetes group were more impressive 
than in the IgA nephropathy patients.79 Use of the Wistar 
rat hypertension model (abdominal aortic banding) has 
demonstrated limitation of left ventricular hypertrophy and 
heart failure by omega 3 fatty acids. High fat diet appeared 
to negate this benefit.80
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